The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea

Gut and Liver

Volumn 8, Issue 6, 2014, Pages 605-611

  Chung, Kwang Hyun ^a   Lee, Dong Ho ^b   Jin, Eunhyo ^a   Cho, Yuri ^a   Seo, Ji Yeon ^a   Kim, Nayoung ^b   Jeong, Sook Hyang ^b   Kim, Jin Wook ^b   Hwang, Jin Hyeok ^b   Shin, Cheol Min ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Anti bacterial agents; Helicobacter pylori; Moxifloxacin; Salvage therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; MOXIFLOXACIN; RABEPRAZOLE; TETRACYCLINE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; ORGANOMETALLIC COMPOUND; QUINOLONE DERIVATIVE; UREA;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BITTER TASTE; CELL INFILTRATION; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC FULLNESS; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; INFLAMMATORY CELL; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA AND VOMITING; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; RAPID UREASE TEST; RETREATMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH BIOPSY; TREATMENT RESPONSE; UREA BREATH TEST; URTICARIA; AGED; BREATH ANALYSIS; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MIDDLE AGED; PATHOLOGY; PEPTIC ULCER; SALVAGE THERAPY; SOUTH KOREA; STOMACH; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BREATH TESTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; RABEPRAZOLE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STOMACH; TETRACYCLINE; TREATMENT FAILURE; TREATMENT OUTCOME; UREA;

EID: 84908691594     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl13303     Document Type: Article

References (30)

1. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000;29:559-578.
2. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011;16 Suppl 1:1-9.
3. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012;61:646-664.
4. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-118.
5. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004;19:407-414.
6. Oh HS, Lee DH, Seo JY, et al. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol 2012;27:504-509.
7. Tsay FW, Tseng HH, Hsu PI, et al. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol 2012;27:498-503.
8. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000;14:91-95.
9. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
10. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057.
11. Gisbert JP, Morena F. Systematic review and meta-analysis: levo-floxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
12. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-496.
13. Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004;64:2347-2377.
14. Kang JM, Kim N, Lee DH, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007;12:623-628.
15. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11:46-51.
16. Bago J, Pevec B, Tomic M, Marusic M, Bakula V, Bago P. Secondline treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009;121:47-52.
17. Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter 2011;16:131-138.
18. Fareed R, Abbas Z, Shah MA. Effect of Helicobacter pylori density on inflammatory activity in stomach. J Pak Med Assoc 2000;50:148-151.
19. Cheon JH, Kim N, Lee DH, et al. Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Korean J Gastroenterol 2005;45:111-117.
20. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;21:1241-1247.
21. Bago P, Vcev A, Tomic M, Rozankovic M, Marusic M, Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007;119:372-378.
22. Sezgin O, Altintaş E, Uçbilek E, Tombak A, Tellioglu B. Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population. Helicobacter 2007;12:518-522.
23. Kilic ZM, Koksal AS, Cakal B, et al. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 2008;53:3133-3137.
24. Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009;14:77-85.
25. Bago J, Majstorovic K, Belosic-Halle Z, et al. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann Clin Microbiol Antimicrob 2010;9:13.
26. Kim JY, Kim N, Park HK, et al. Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea. Korean J Gastroenterol 2011;58:74-81.
27. Lee JW, Kim N, Nam RH, et al. Mutations of Helicobacter pylori associated with fluoroquinolone resistance in Korea. Helicobacter 2011;16:301-310.
28. Liu G, Xu X, He L, et al. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. Helicobacter 2011;16:356-362.
29. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413-422.
30. Malfertheiner P, Megraud F, O'Morain C, et al. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997;9:1-2.